CalciMedica (CALC) Net Income towards Common Stockholders (2019 - 2026)

CalciMedica (CALC) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$5.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 14.6% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.3 million (down 26.6% YoY) and the FY2025 annual result came in at -$115.8 million, down 745.05% from the prior year.
• Net Income towards Common Stockholders declined to -$5.9 million in Q1 2026, from -$4.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $130000.0 in Q1 2024 to a low of -$19.3 million in Q1 2023.
• A 5-year average of -$5.6 million and a median of -$4.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 100.67% — and 2025, when it tumbled 5441.54%.
• Tracing CALC's Net Income towards Common Stockholders over 5 years: stood at -$2.9 million in 2022, then tumbled by 43.16% to -$4.1 million in 2023, then retreated by 2.7% to -$4.3 million in 2024, then slipped by 10.62% to -$4.7 million in 2025, then slipped by 25.9% to -$5.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.